A peptide NK1 receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Vapreotide (trifluoroacetate salt)

Item No. 24558

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-tryptophanamide, cyclic (2→7)-disulfide, trifluoroacetate salt
Synonyms
  • BMY 41606
  • Octastatin
  • RC 160
Molecular Formula
C57H70N12O9S2 • XCF3COOH
Formula Weight
1131.4
Purity
≥95%
Formulation (Request formulation change)
A lyophilized powder
Solubility(Learn about Variance in Solubility)
Water: 1 mg/ml
SMILES
O=C(N[C@@H](C(C)C)C(N[C@H](C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N)=O)=O)CSSC[C@H](NC([C@H](N)CC3=CC=CC=C3)=O)C4=O)=O)[C@H](CCCCN)NC([C@@H](CC5=CNC6=C5C=CC=C6)NC([C@@](CC7=CC=C(O)C=C7)([H])N4)=O)=O.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C57H70N12O9S2.C2HF3O2/c1-32(2)49-57(78)68-48(55(76)64-44(50(60)71)26-35-28-61-41-16-8-6-14-38(35)41)31-80-79-30-47(67-51(72)40(59)24-33-12-4-3-5-13-33)56(77)65-45(25-34-19-21-37(70)22-20-34)53(74)66-46(27-36-29-62-42-17-9-7-15-39(36)42)54(75)63-43(52(73)69-49)18-10-11-23-58;3-2(4,5)1(6)7/h3-9,12-17,19-22,28-29,32,40,43-49,61-62,70H,10-11,18,23-27,30-31,58-59H2,1-2H3,(H2,60,71)(H,63,75)(H,64,76)(H,65,77)(H,66,74)(H,67,72)(H,68,78)(H,69,73);(H,6,7)/t40-,43+,44+,45+,46-,47+,48+,49+;/m1./s1
InChi Key
LVZIATZDHWYHID-NCACADTJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $95

    Add

    1 mg

    $149

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Vapreotide is a peptide neurokinin-1 receptor (NK1) antagonist and analog of somatostatin (IC50 = 330 nM in a radioligand binding assay).1 It inhibits increases in vascular permeability stimulated by substance P (Item No. 24035) in a concentration-dependent manner in isolated guinea pig trachea and main bronchi. Vapreotide (8 nmol per animal) reduces substance P-induced biting and scratching in mice. It increases reaction time to heat stimuli in the hot plate and tail flick tests when administered at a dose of 512 μg/kg, indicating antinociceptive activity in mice.2 Vapreotide reduces plasma growth hormone (GH) increases induced by phenobarbital (Item Nos. 9001494 | 20987), morphine (Item No. ISO60147), and chlorpromazine (Item No. 16129), hypoglycemia-induced glucagon elevation, and glucose-induced insulin secretion in rats.3 It also decreases tumor weight and volume in a hamster model of pancreatic ductal adenocarcinoma and suppresses tumor growth and reduces GH secretion in SK-ES-1 and MNNG/HOS osteosarcoma mouse xenograft models.4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bétoin, F., Advenier, C., Fardin, V., et al. In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin. Eur. J. Pharmacol. 279(2-3), 241-249 (1995).

    2. Eschalier, A., Aumaître, O., Ardid, D., et al. Long-lasting antinociceptive effect of RC-160, a somatostatin analog, in mice and rats. Eur. J. Pharmacol. 199(1), 119-121 (1991).

    3. Karashima, T., Cai, R.Z., and Schally, A.V. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sci. 41(8), 1011-1019 (1987).

    4. Paz-Bouza, J.I., Redding, T.W., and Schally, A.V. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 84(4), 1112-1116 (1987).

    5. Pinski, J., Schally, A.V., Halmos, G., et al. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int. J. Cancer. 65(6), 870-874 (1996).